Literature DB >> 8413873

Duration of intracranial pressure monitoring does not predict daily risk of infectious complications.

J A Winfield1, P Rosenthal, R K Kanter, G Casella.   

Abstract

A group of 205 patients (115 children and 90 adults) with a total of 212 intracranial pressure (ICP) monitors were retrospectively studied with attention to daily cerebrospinal fluid cultures, duration of monitoring, associated cranial injuries, and hospital site of the ICP monitor (intensive care unit or operating room). Only closed ICP monitoring systems without irrigation or compliance testing were used, and all patients received antibiotics as prophylaxis throughout the monitoring period. There were no complications associated with monitor placement. Incidence histograms and regression analysis were used to determine the daily risk of subsequent infections, in addition to evaluating the cumulative risk of infection, as has been previously described in the literature. No relation between the duration of ICP monitoring and the rate of daily infection through the period of maximal monitoring (1-2 weeks) was found in this series. The overall incidence of infection was 7.1% with a median duration of monitoring of 7.2 days. The age of the patient (adult vs. child), site of ICP monitor placement, and nature of the underlying disease (trauma vs. nontrauma) had no significant effect on the development of monitor-related infections in our study. These data indicate that the decision to continue ICP monitoring can be based solely on the clinical necessity for further monitoring rather than on concerns for monitor removal to prevent infection.

Entities:  

Mesh:

Year:  1993        PMID: 8413873     DOI: 10.1227/00006123-199309000-00011

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  19 in total

1.  Complications of brain tissue pressure monitoring with a fiberoptic device.

Authors:  A Bekar; S Gören; E Korfali; K Aksoy; S Boyaci
Journal:  Neurosurg Rev       Date:  1998       Impact factor: 3.042

2.  The risk factors of external ventricular drainage-related infection at hospital kuala lumpur: an observational study.

Authors:  Mohamad Azhari Omar; Mohd Saffari Mohd Haspani
Journal:  Malays J Med Sci       Date:  2010-07

3.  MRI-compatible titanium ventriculostomy kit: technical note.

Authors:  C Schaller; C Pavlidis
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

4.  Continuous antibiotic prophylaxis and cerebral spinal fluid infection in patients with intracranial pressure monitors.

Authors:  John J Flibotte; Kim En Lee; Walter J Koroshetz; Jonathan Rosand; Colin T McDonald
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

5.  Relative risks of ventriculostomy infection and morbidity.

Authors:  C G Paramore; D A Turner
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

6.  Infection related to intracranial pressure monitors in adults: analysis of risk factors and antibiotic prophylaxis.

Authors:  J A Rebuck; K R Murry; D H Rhoney; D B Michael; W M Coplin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-09       Impact factor: 10.154

7.  Camino intracranial pressure monitor: prospective study of accuracy and complications.

Authors:  R M Martínez-Mañas; D Santamarta; J M de Campos; E Ferrer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-07       Impact factor: 10.154

8.  Malplacement of ventricular catheters by neurosurgeons: a single institution experience.

Authors:  Andrea Saladino; J Bradley White; Eelco F M Wijdicks; Giuseppe Lanzino
Journal:  Neurocrit Care       Date:  2008-10-16       Impact factor: 3.210

9.  Early diagnosis of external ventricular drainage infection: results of a prospective study.

Authors:  W Pfisterer; M Mühlbauer; T Czech; A Reinprecht
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-07       Impact factor: 10.154

10.  Central nervous system infections in the neurointensive care unit.

Authors:  Fred Rincon; Neeraj Badjatia
Journal:  Curr Treat Options Neurol       Date:  2006-03       Impact factor: 3.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.